ORGANON & CO Financials

OGN

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows ORGANON & CO (OGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

$6.4B

YoY+2.2%

5Y CAGR-3.8%

ORGANON & CO generated $6.4B in revenue in fiscal year 2024. This represents an increase of 2.2% from the prior year.

EBITDA

N/A

Free Cash Flow

$764.0M

YoY+39.4%

5Y CAGR-23.6%

ORGANON & CO generated $764.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 39.4% from the prior year.

Net Income

$864.0M

YoY-15.5%

5Y CAGR-23.1%

ORGANON & CO reported $864.0M in net income in fiscal year 2024. This represents a decrease of 15.5% from the prior year.

EPS (Diluted)

$3.33

YoY-16.5%

5Y CAGR-23.5%

ORGANON & CO earned $3.33 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 16.5% from the prior year.

Cash & Debt

$675.0M

YoY-2.6%

ORGANON & CO held $675.0M in cash against $8.9B in long-term debt as of fiscal year 2024.

Dividends Per Share

$1.12

YoY+0.0%

ORGANON & CO paid $1.12 per share in dividends in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Shares Outstanding

258M

YoY+0.9%

ORGANON & CO had 258M shares outstanding in fiscal year 2024. This represents an increase of 0.9% from the prior year.

Gross Margin

58.0%

YoY-1.8pp

5Y CAGR-12.7pp

ORGANON & CO's gross margin was 58.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 1.8 percentage points from the prior year.

Operating Margin

N/A

Net Margin

13.5%

YoY-2.8pp

5Y CAGR-27.9pp

ORGANON & CO's net profit margin was 13.5% in fiscal year 2024, showing the share of revenue converted to profit. This is down 2.8 percentage points from the prior year.

Return on Equity

183.1%

5Y CAGR+137.3pp

ORGANON & CO's ROE was 183.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.

R&D Spending

$469.0M

YoY-11.2%

5Y CAGR+16.3%

ORGANON & CO invested $469.0M in research and development in fiscal year 2024. This represents a decrease of 11.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$175.0M

YoY-30.3%

5Y CAGR+13.7%

ORGANON & CO invested $175.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 30.3% from the prior year.

OGN Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	$6.4B+2.2%	$6.3B+1.4%	$6.2B-2.1%	$6.3B-3.5%	$6.5B-16.0%	$7.8B
Cost of Revenue	$2.7B+6.9%	$2.5B+9.6%	$2.3B-3.7%	$2.4B+12.4%	$2.1B-6.8%	$2.3B
Gross Profit	$3.7B-0.9%	$3.7B-3.4%	$3.9B-1.1%	$3.9B-11.1%	$4.4B-19.8%	$5.5B
R&D Expenses	$469.0M-11.2%	$528.0M+12.1%	$471.0M+38.9%	$339.0M+61.4%	$210.0M-4.5%	$220.0M
SG&A Expenses	$1.8B-7.0%	$1.9B+11.1%	$1.7B+2.2%	$1.7B+23.0%	$1.4B-6.0%	$1.4B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$520.0M-1.3%	$527.0M+24.9%	$422.0M+63.6%	$258.0M	$0	$0
Income Tax	-$57.0M+83.7%	-$350.0M-270.7%	$205.0M+15.2%	$178.0M-64.1%	$496.0M+27.2%	$390.0M
Net Income	$864.0M-15.5%	$1.0B+11.6%	$917.0M-32.1%	$1.4B-37.5%	$2.2B-32.9%	$3.2B
EPS (Diluted)	$3.33-16.5%	$3.99+11.1%	$3.59-32.4%	$5.31-37.7%	$8.52-32.9%	$12.69

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$1.6B+0.5%	$1.6B+5.4%	$1.5B-5.0%	$1.6B+0.6%	$1.6B-1.6%	$1.6B-0.9%	$1.6B+1.5%	$1.6B
Cost of Revenue	$745.0M+3.5%	$720.0M+7.1%	$672.0M-3.4%	$696.0M+5.6%	$659.0M-1.3%	$668.0M+0.5%	$665.0M-2.6%	$683.0M
Gross Profit	$857.0M-1.9%	$874.0M+3.9%	$841.0M-6.1%	$896.0M-2.9%	$923.0M-1.7%	$939.0M-1.9%	$957.0M+4.6%	$915.0M
R&D Expenses	$84.0M-11.6%	$95.0M-1.0%	$96.0M-26.2%	$130.0M+17.1%	$111.0M-4.3%	$116.0M+3.6%	$112.0M-16.4%	$134.0M
SG&A Expenses	$415.0M-8.4%	$453.0M+7.9%	$420.0M-10.6%	$470.0M+11.4%	$422.0M-3.4%	$437.0M+1.4%	$431.0M-8.1%	$469.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$128.0M-2.3%	$131.0M+5.6%	$124.0M-6.1%	$132.0M+4.8%	$126.0M-3.8%	$131.0M0.0%	$131.0M+1.6%	$129.0M
Income Tax	$83.0M-1.2%	$84.0M+500.0%	$14.0M-30.0%	$20.0M+113.2%	-$152.0M-480.0%	$40.0M+14.3%	$35.0M+107.9%	-$442.0M
Net Income	$160.0M+10.3%	$145.0M+66.7%	$87.0M-20.2%	$109.0M-69.6%	$359.0M+84.1%	$195.0M-3.0%	$201.0M-63.2%	$546.0M
EPS (Diluted)	$0.61+8.9%	$0.56+69.7%	$0.33-21.4%	$0.42-69.6%	$1.38+84.0%	$0.75-3.8%	$0.78-63.2%	$2.12

OGN Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$13.1B+8.6%	$12.1B+10.1%	$11.0B+2.6%	$10.7B+5.7%	$10.1B	N/A
Current Assets	$4.3B-3.5%	$4.5B+14.7%	$3.9B+4.5%	$3.8B+5.4%	$3.6B	N/A
Cash & Equivalents	$675.0M-2.6%	$693.0M-1.8%	$706.0M-4.2%	$737.0M+6041.7%	$12.0M	N/A
Inventory	$1.3B+0.5%	$1.3B+31.1%	$1.0B+9.6%	$915.0M+0.2%	$913.0M	N/A
Accounts Receivable	$1.4B-22.1%	$1.7B+18.2%	$1.5B+6.7%	$1.4B+33.1%	$1.0B	N/A
Goodwill	$4.7B+1.7%	$4.6B0.0%	$4.6B0.0%	$4.6B0.0%	$4.6B	N/A
Total Liabilities	$12.6B+4.1%	$12.1B+2.4%	$11.8B-2.8%	$12.2B+163.7%	$4.6B	N/A
Current Liabilities	$2.7B-6.9%	$2.9B+16.2%	$2.5B-3.3%	$2.6B-2.8%	$2.7B	N/A
Long-Term Debt	$8.9B+1.2%	$8.8B-1.7%	$8.9B-2.4%	$9.1B	$0	N/A
Total Equity	$472.0M+774.3%	-$70.0M+92.2%	-$892.0M+40.8%	-$1.5B-127.5%	$5.5B-22.0%	$7.0B
Retained Earnings	$1.0B+128.0%	$443.0M+233.8%	-$331.0M+66.8%	-$998.0M	$0	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$13.6B+0.4%	$13.5B+2.6%	$13.2B+0.4%	$13.1B+2.7%	$12.8B+4.9%	$12.2B+2.2%	$11.9B-1.4%	$12.1B
Current Assets	$4.7B+1.8%	$4.6B+5.7%	$4.4B+0.5%	$4.3B-8.6%	$4.8B+5.5%	$4.5B+7.5%	$4.2B-6.9%	$4.5B
Cash & Equivalents	$672.0M+12.2%	$599.0M+9.5%	$547.0M-19.0%	$675.0M-11.5%	$763.0M+8.4%	$704.0M+22.4%	$575.0M-17.0%	$693.0M
Inventory	$1.5B+2.3%	$1.5B+6.8%	$1.4B+3.1%	$1.3B-4.5%	$1.4B+7.5%	$1.3B+1.9%	$1.3B-4.0%	$1.3B
Accounts Receivable	$1.5B0.0%	$1.5B+1.9%	$1.5B+7.3%	$1.4B-19.4%	$1.7B+4.2%	$1.6B+4.5%	$1.5B-11.3%	$1.7B
Goodwill	$4.7B0.0%	$4.7B0.0%	$4.7B0.0%	$4.7B+1.7%	$4.6B0.0%	$4.6B0.0%	$4.6B0.0%	$4.6B
Total Liabilities	$12.6B-0.9%	$12.8B+1.2%	$12.6B-0.1%	$12.6B+3.0%	$12.3B+2.1%	$12.0B+1.4%	$11.8B-2.3%	$12.1B
Current Liabilities	$2.7B-4.2%	$2.8B+6.9%	$2.6B-3.8%	$2.7B-2.6%	$2.8B+1.3%	$2.8B+8.3%	$2.5B-12.8%	$2.9B
Long-Term Debt	$8.8B0.0%	$8.8B-1.7%	$8.9B+0.9%	$8.9B+1.4%	$8.7B+1.1%	$8.6B-0.7%	$8.7B-0.5%	$8.8B
Total Equity	$906.0M+23.6%	$733.0M+35.2%	$542.0M+14.8%	$472.0M-4.3%	$493.0M+242.4%	$144.0M+200.0%	$48.0M+168.6%	-$70.0M
Retained Earnings	$1.3B+13.3%	$1.2B+13.4%	$1.0B+1.6%	$1.0B+3.6%	$975.0M+41.3%	$690.0M+20.4%	$573.0M+29.3%	$443.0M

OGN Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	$939.0M+17.5%	$799.0M-6.9%	$858.0M-60.3%	$2.2B-5.4%	$2.3B-24.4%	$3.0B
Capital Expenditures	$175.0M-30.3%	$251.0M+28.1%	$196.0M+2.1%	$192.0M-24.7%	$255.0M+177.2%	$92.0M
Free Cash Flow	$764.0M+39.4%	$548.0M-17.2%	$662.0M-66.4%	$2.0B-3.0%	$2.0B-30.7%	$2.9B
Investing Cash Flow	-$513.0M-97.3%	-$260.0M+38.1%	-$420.0M	N/A	N/A	N/A
Financing Cash Flow	-$368.0M+35.3%	-$569.0M-31.4%	-$433.0M	N/A	N/A	N/A
Dividends Paid	$297.0M+1.0%	$294.0M+1.4%	$290.0M+100.0%	$145.0M	$0	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	$75.0M	N/A	N/A	N/A	$76.0M	N/A
Capital Expenditures	N/A	N/A	$32.0M	N/A	N/A	N/A	$46.0M	N/A
Free Cash Flow	N/A	N/A	$43.0M	N/A	N/A	N/A	$30.0M	N/A
Investing Cash Flow	N/A	N/A	-$172.0M	N/A	N/A	N/A	-$96.0M	N/A
Financing Cash Flow	N/A	N/A	-$75.0M	N/A	N/A	N/A	-$74.0M	N/A
Dividends Paid	N/A	N/A	$71.0M	N/A	N/A	N/A	$70.0M	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OGN Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	58.0%-1.8pp	59.8%-3.0pp	62.8%+0.6pp	62.2%-5.3pp	67.6%-3.2pp	70.8%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	13.5%-2.8pp	16.3%+1.5pp	14.8%-6.6pp	21.4%-11.6pp	33.1%-8.3pp	41.4%
Return on Equity	183.1%	N/A	N/A	N/A	39.4%-6.4pp	45.7%
Return on Assets	6.6%-1.9pp	8.5%+0.1pp	8.4%-4.3pp	12.7%-8.7pp	21.4%	N/A
Current Ratio	1.60+0.1	1.54-0.0	1.56+0.1	1.45+0.1	1.33	N/A
Debt-to-Equity	18.77+143.8	-125.01-115.0	-9.98-3.9	-6.05-6.1	0.00	N/A
FCF Margin	11.9%+3.2pp	8.8%-2.0pp	10.7%-20.5pp	31.2%+0.2pp	31.1%-6.6pp	37.6%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	53.5%-1.3pp	54.8%-0.7pp	55.6%-0.7pp	56.3%-2.1pp	58.3%-0.1pp	58.4%-0.6pp	59.0%+1.7pp	57.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	10.0%+0.9pp	9.1%+3.3pp	5.8%-1.1pp	6.9%-15.8pp	22.7%+10.6pp	12.1%-0.3pp	12.4%-21.8pp	34.2%
Return on Equity	17.7%-2.1pp	19.8%+3.7pp	16.1%-7.0pp	23.1%-49.7pp	72.8%-62.6pp	135.4%-283.3pp	418.8%	N/A
Return on Assets	1.2%+0.1pp	1.1%+0.4pp	0.7%-0.2pp	0.8%-2.0pp	2.8%+1.2pp	1.6%-0.1pp	1.7%-2.8pp	4.5%
Current Ratio	1.75+0.1	1.65-0.0	1.67+0.1	1.60-0.1	1.70+0.1	1.64-0.0	1.65+0.1	1.54
Debt-to-Equity	9.69-2.3	11.98-4.5	16.49-2.3	18.77+1.0	17.73-42.3	60.05-121.3	181.35+306.4	-125.01
FCF Margin	N/A	N/A	2.8%	N/A	N/A	N/A	1.8%	N/A

Financial Health Signals

Financial Profile 48/100

Profitability

N/A

Growth

Leverage

Liquidity

Cash Flow

Returns

100

Based on FY2024 annual data. Scores normalized against common benchmarks.

Piotroski F-Score Neutral

5/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Cash-Backed

1.09x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Similar Companies

Grifols S A GRFS

$6.3B

Indivior Pharmaceuticals Inc INDV

$4.2B

Bausch Health Companies Inc BHC

$2.2B

Amneal Pharmaceuticals Inc AMRX

$4.6B

Hutchmed (China) Limited HCM

$2.5B

Frequently Asked Questions

What is ORGANON & CO's annual revenue?

ORGANON & CO (OGN) reported $6.4B in total revenue for fiscal year 2024. This represents a 2.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ORGANON & CO's revenue growing?

ORGANON & CO (OGN) revenue grew by 2.2% year-over-year, from $6.3B to $6.4B in fiscal year 2024.

Is ORGANON & CO profitable?

Yes, ORGANON & CO (OGN) reported a net income of $864.0M in fiscal year 2024, with a net profit margin of 13.5%.

What is ORGANON & CO's earnings per share (EPS)?

ORGANON & CO (OGN) reported diluted earnings per share of $3.33 for fiscal year 2024. This represents a -16.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

How much debt does ORGANON & CO have?

As of fiscal year 2024, ORGANON & CO (OGN) had $675.0M in cash and equivalents against $8.9B in long-term debt.

What is ORGANON & CO's gross margin?

ORGANON & CO (OGN) had a gross margin of 58.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is ORGANON & CO's net profit margin?

ORGANON & CO (OGN) had a net profit margin of 13.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Does ORGANON & CO pay dividends?

Yes, ORGANON & CO (OGN) paid $1.12 per share in dividends during fiscal year 2024.

What is ORGANON & CO's return on equity (ROE)?

ORGANON & CO (OGN) has a return on equity of 183.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is ORGANON & CO's free cash flow?

ORGANON & CO (OGN) generated $764.0M in free cash flow during fiscal year 2024. This represents a 39.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ORGANON & CO's operating cash flow?

ORGANON & CO (OGN) generated $939.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are ORGANON & CO's total assets?

ORGANON & CO (OGN) had $13.1B in total assets as of fiscal year 2024, including both current and long-term assets.

What are ORGANON & CO's capital expenditures?

ORGANON & CO (OGN) invested $175.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does ORGANON & CO spend on research and development?

ORGANON & CO (OGN) invested $469.0M in research and development during fiscal year 2024.

How many shares does ORGANON & CO have outstanding?

ORGANON & CO (OGN) had 258M shares outstanding as of fiscal year 2024.

What is ORGANON & CO's current ratio?

ORGANON & CO (OGN) had a current ratio of 1.60 as of fiscal year 2024, which is generally considered healthy.

What is ORGANON & CO's debt-to-equity ratio?

ORGANON & CO (OGN) had a debt-to-equity ratio of 18.77 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ORGANON & CO's return on assets (ROA)?

ORGANON & CO (OGN) had a return on assets of 6.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is ORGANON & CO's Piotroski F-Score?

ORGANON & CO (OGN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are ORGANON & CO's earnings high quality?

ORGANON & CO (OGN) has an earnings quality ratio of 1.09x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

How financially healthy is ORGANON & CO?

ORGANON & CO (OGN) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.